Back to top

Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler

Piper Sandler analyst Biren Amin maintained a Buy rating on Aclaris Therapeutics today and set a price target of $11.00. Amin covers the Healthcare...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Aclaris Therapeutics, Inc. (ACRS)